Annual report
4272.TEDINET S100W41Y
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥222.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥201.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥198.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥184.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥173.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥7.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥22.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥12.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.0bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.2bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥22.0bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥17.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥17.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥4.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥373.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥363.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥322.9bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥315.5bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥294.5bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.2bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥92.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥268.5bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥270.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥255.0bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥246.4bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥228.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥55.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥56.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥47.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥25.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥23.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥24.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥27.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥19.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥4.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥11.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥8.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥107.17 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.8 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.36 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.7 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.62 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥107.16 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥89.33 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥101.65 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.61 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,673.24 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,625.18 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,532.35 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,459.06 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,332.06 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 71.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.7% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.2% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.6% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,979 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 5,902 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,782 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 5,703 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,664 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥130.5bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥120.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥128.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥124.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥115.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥4.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | −¥3.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥13.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.2bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥12.8bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥967m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥11.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥666m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥12.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥22.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥265.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥261.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥237.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥236.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥230.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥88.1bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥76.5bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥177.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥185.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥185.2bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥184.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥180.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥16.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥69.65 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.02 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.33 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.63 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.38 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥60 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,109.15 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,116.51 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,117.38 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,098.36 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,056.38 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 66.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.0% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.8% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 165,003,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 170,503,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 170,503,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 170,503,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,423 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 2,419 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 2,391 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 2,398 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 2,401 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥593m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥196m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥196m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥61.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥9.2bn |
| Fine Chemicals Business Unitreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥12.6bn |
| Fine Chemicals Business Unitreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.8bn |
| Fine Chemicals Business Unitreportable segment | employees | at 2025-03-31 | 1359 pure |
| Fine Chemicals Business Unitreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥66.4bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥66.2bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥196m |
| Fine Chemicals Business Unitreportable segment | segment assets | at 2025-03-31 | ¥94.5bn |
| Fine Chemicals Business Unitreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9.9bn |
| Life Science Business Unitreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥4.8bn |
| Life Science Business Unitreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Life Science Business Unitreportable segment | employees | at 2025-03-31 | 953 pure |
| Life Science Business Unitreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥65.0bn |
| Life Science Business Unitreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥65.0bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Life Science Business Unitreportable segment | segment assets | at 2025-03-31 | ¥86.7bn |
| Life Science Business Unitreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| Mobility And Imaging Business Unitreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥9.0bn |
| Mobility And Imaging Business Unitreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Mobility And Imaging Business Unitreportable segment | employees | at 2025-03-31 | 3412 pure |
| Mobility And Imaging Business Unitreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥91.4bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥91.4bn |
| Mobility And Imaging Business Unitreportable segment | segment assets | at 2025-03-31 | ¥130.8bn |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.3bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥26.5bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥13.3bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥222.8bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥222.6bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥196m |
| —segment total | segment assets | at 2025-03-31 | ¥312.0bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥29.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥26.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥13.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥222.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥222.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥196m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥312.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥29.6bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥903m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥498m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥170m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥170m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥71.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥8.3bn |
| Fine Chemicals Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Fine Chemicals Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.6bn |
| Fine Chemicals Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥57.2bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥57.1bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥169m |
| Fine Chemicals Business Unitreportable segment | segment assets | at 2024-03-31 | ¥82.6bn |
| Fine Chemicals Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.2bn |
| Life Science Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| Life Science Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Life Science Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥63.5bn |
| Life Science Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥63.5bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| Life Science Business Unitreportable segment | segment assets | at 2024-03-31 | ¥84.8bn |
| Life Science Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Mobility And Imaging Business Unitreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥6.8bn |
| Mobility And Imaging Business Unitreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥7.0bn |
| Mobility And Imaging Business Unitreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥81.2bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥81.2bn |
| Mobility And Imaging Business Unitreportable segment | segment assets | at 2024-03-31 | ¥124.2bn |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥18.4bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥13.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥202.0bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥201.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥170m |
| —segment total | segment assets | at 2024-03-31 | ¥291.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥18.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥202.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥201.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥170m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥291.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥15.6bn |
| Fine Chemicals Business Unitreportable segment | employees | at 2025-03-31 | 685 pure |
| Life Science Business Unitreportable segment | employees | at 2025-03-31 | 897 pure |
| Mobility And Imaging Business Unitreportable segment | employees | at 2025-03-31 | 588 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,282
| Item | Context | Value | Unit |
|---|---|---|---|
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row35Member | 8.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row36Member | 50 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row36Member | 100.0 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row37Member | 2.5 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row37Member | 2.1 | |
| Research and development expenses research and development activities | CurrentYearDuration | 15000000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 3700000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 4100000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 5900000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1200000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 26600000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 9400000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 9000000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 6600000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1400000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 165003570 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 160000000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 165003570 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 160000000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 37 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 44 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 256 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 240 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 19838 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 20458 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 565315 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 73263 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 145704 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 531562 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 359 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 331285 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 1647488 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 254770 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.3431 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0445 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.0884 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.3226 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0002 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.2011 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 23299000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.1457 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 10175000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0636 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 9563000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0598 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |